500735-47-7

Basic information

• Product Name: OLOMOUCINE II
• Synonyms: Nsc736738;Olomoucine ii, 6-[(2-hydroxybenzyl)amino]-2-[1-(hydroxymethyl)propylamino]- 9-isopropylpurine;2-[[[2-[[(1R)-1-(Hydroxymethyl)propyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]methyl]phenol
• CAS NO: 500735-47-7
• Molecular Formula: C19H26N6O2
• Molecular Weight: 370.454
• Mol File: 500735-47-7.mol

Chemical Properties

• Appearance: /powder
• Density: 1.32
• Storage Temp.: −20°C
• Solubility: chloroform: 50 mg/mL, soluble
• CAS DataBase Reference: OLOMOUCINE II(CAS DataBase Reference)
• NIST Chemistry Reference: OLOMOUCINE II(500735-47-7)
• EPA Substance Registry System: OLOMOUCINE II(500735-47-7)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• Hazardous Substances Data: 500735-47-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
OLOMOUCINE II is used as a pharmaceutical agent for its potent inhibitory effects on Cdk1/B, which plays a crucial role in cell cycle regulation. Its ability to inhibit this enzyme makes it a potential candidate for the development of anti-cancer therapies.
Used in Cancer Research:
In cancer research, OLOMOUCINE II is utilized as a tool to study the role of Cdk1/B in the progression of cancer and to understand the mechanisms of action that contribute to its cytotoxic effects on various cancer cell lines.
Used in Drug Development:
OLOMOUCINE II serves as a lead compound in drug development for the creation of novel therapeutics targeting Cdk1/B. Its high potency and selectivity make it a valuable starting point for the design of new drugs with improved efficacy and reduced side effects in cancer treatment.

Biochem/physiol Actions

Cell permeable: yes

Upstream product

• 96-20-8 2-aminobutanol 
• 500568-72-9 2-[(2-chloro-9-isopropyl-9H-purin-6-ylamino)-methyl]-phenol 
• 203436-45-7 2,6-dichloro-9-isopropyl-9H-purine 
• 932-30-9 2-Hydroxybenzylamine 

Relevant articles and documents

Synthesis and biological activity of olomoucine II.

Based on our previous experiences with synthesis of purines, novel 2,6,9-trisubstituted purine derivatives were prepared and assayed for the ability to inhibit CDK1/cyclin B kinase. One of newly synthesized compounds designated as olomoucine II, 6-[(2-hydroxybenzyl)amino]-2-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine, displays 10 times higher inhibitory activity than roscovitine, potent and specific CDK1 inhibitor. Olomoucine II in vitro cytotoxic activity exceeds purvalanol A, the most potent CDK inhibitor, as it kills the CEM cells with IC(50) value of 3.0 microM.